To select the appropriate propofol and ropivacaine concentrations, cell viability was assessed using the
Cell Counting Kit-8 (CCK-8; Beyotime Institute of Biotechnology) according to the manufacturer's instruction. Cardiomyocytes were seeded at a density of 3×10
3 cells in 96-well plates in sextuplicate and incubated overnight in the complete DMEM/F12 with or without 500
µmol/l CoCl
2 in an atmosphere with 5% CO
2 at 37°C. After removing the culture medium, cells were treated with propofol (100, 50, 25, 12.5, 6.25 and 0
µg/ml) or ropivacaine at different concentrations (300, 150, 75, 37.5, 18.75 and 0
µg/ml in the absence of Cocl2 treatment experiments; 100, 50, 25, 12.5 and 0
µg/ml in the 500
µmol/l Cocl2-pretreatment experiments) in fresh medium, repeated eight times, for 48 h at 37°C. In addition, to determine the synergistic interactions between propofol and ropivacaine, AC16 and HCM cells were treated by 25
µg/ml of propofol and different ropivacaine concentrations (200, 100, 50, 25, 12.5 and 0
µg/ml) for 48 h at 37°C. The supernatants were discarded and the CCK-8 solution, (dilution, 1:10) was added to each well in complete DMEM/F12, and the cells were incubated for 2 h at 37°C. Absorbance at 450 nm was measured using a microplate reader (cat. no.
MQX200; BioTek Instruments, Inc.). All experiments were repeated four times.
Han L., Zhuo Q., Zhou Y, & Qian Y. (2020). Propofol protects human cardiac cells against chemical hypoxiainduced injury by regulating the JNK signaling pathways. Experimental and Therapeutic Medicine, 19(3), 1864-1870.